Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Colaboración

Año: 2024

Siefker-Radtke, AO; Matsubara, N; Park, SH; Huddart, RA; Burgess, EF; Özgüroglu, M; Valderrama, BP; Laguerre, B; Basso, U; Triantos, S; Akapame, S; Kean, Y; Deprince, K; Mukhopadhyay, S; Loriot, Y

Título: ANNALS OF ONCOLOGY

• D1